Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | CCR1 | P32246 | 3/20 | 0.54 |
| ▸ | CCR5 | P51681 | 3/20 | 0.54 |
| ▸ | CCR8 | P51685 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | METAP1 | P53582 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.54 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1893518 | 0.78 | CYP2A6 (0.53) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL30989133 | 0.76 | KDM4E (0.72) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL1566968 | 0.76 | KDM4E (0.72) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL30989132 | 0.76 | KDM4E (0.72) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL998558 | 0.76 | CYP2A6 (0.67) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL30338847 | 0.76 | CYP2A6 (0.67) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL21338494 | 0.76 | KDM4E (0.60) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL29187795 | 0.75 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL24272520 | 0.74 | KDM4E (0.54) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL20227407 | 0.74 | KDM4E (0.54) | KDM4ELMNACCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | claimed |
| EP-4247376-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| CN-116507608-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2023-07-28 | — | — | CN | claimed |
| WO-2022109268-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | claimed |
| EP-4330236-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-4247376-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| CN-116507608-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2022109268-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-7705023-B2 | Indoles useful in the treatment of inflammation | BIOLIPOX AB (SE) | 2010-04-27 | — | — | US | disclosed |
| EP-1778632-B1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| US-20070287715-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287715-A1 | Indoles Useful in the Treatment of Inflammation | PTGS1, IDO1, PTGES | KDM4E 2368/4885LMNA 3274/4885CCR1 582/4885 |
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NLRP3, NLRP1, NOD1 | KDM4E 3822/4885LMNA 2009/4885CCR1 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.